Physician profile
Aaron J Smyth
NPI 1053575357
$2,394.86
in general payments reported to CMS, 2019-2025
30 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $364 · 2021: $670 · 2022: $97.15 · 2023: $77.28 · 2024: $127 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.32 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.22 | 2021-2025 | |
| Novo Nordisk INC | $308.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.34 | 2019-2025 | Jardiance |
| Pfizer INC. | $185.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $177.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $177.35 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $128.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $120.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $97.64 | 2021 | |
| Allergan, INC. | $84.90 | 2019-2020 | |
| Astellas Pharma US INC | $59.47 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.68 | 2019 | |
| Lilly USA, LLC | $50.64 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $50.40 | 2020 | |
| Inogen, INC. | $36.84 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27.58 | 2022-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $27.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.06 | 2021 | |
| Amarin Pharma, INC. | $26.38 | 2020 | |
| Exact Sciences Corporation | $18.65 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $17.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2022 | |
| Medtronic, INC. | $16.00 | 2023 | Minimed 780g |
| Inspire Medical Systems, INC. | $15.05 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $14.69 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.64 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2020 | |
| Currax Pharmaceuticals LLC | $12.89 | 2020 | |
| Eisai INC. | $12.74 | 2021 | |
| Mylan Specialty L.P. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Smyth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.